Fibrosis: The Invisible Enemy of Liver Health
Hepatic fibrosis refers to the excessive buildup of scar tissue in the liver due to chronic liver damage, while cirrhosis is the advanced stage of hepatic fibrosis where the scarring becomes so extensive that it significantly disrupts the usual structure and function of the liver, leading to complications like portal hypertension and liver failure; essentially, fibrosis is the early stage of scarring, and cirrhosis is the severe, progressed form of that scarring.
Fibrosis occurs when scar tissue accumulates in the liver. A healthy liver is soft and smooth, but as scarring increases, it becomes hard and uneven.
 |
| Leaver fibrosis stages |
Liver fibrosis is a pathological condition marked by excessive accumulation of extracellular matrix (ECM) proteins, primarily collagen, within the liver tissue in response to chronic liver injury. It represents a wound-healing response of the liver that, under normal circumstances, helps minor injuries. However, sustained liver damage leads to persistent fibrosis, eventually disrupting liver architecture and functionality.
If left untreated, liver fibrosis progresses to cirrhosis, liver failure, and hepatocellular carcinoma (HCC). The biology of liver fibrosis revolves around the activation of hepatic stellate cells (HSCs), chronic inflammation, dysregulated ECM production, and impaired ECM degradation.
What is the relation between chronic liver damage and liver fibrosis?
All chronic liver diseases (CLD) have the potential to progress to liver fibrosis, a condition characterised by the accumulation of scar tissue in the liver. Chronic liver damage and liver fibrosis are closely interlinked, where persistent liver injury from various sources triggers a progressive fibrotic response in the liver tissue. Fibrosis is the wound-healing process that goes wrong in response to sustained liver injury. Over time, continuous liver damage transforms reversible fibrosis into irreversible cirrhosis if untreated. Understanding the relationship between chronic liver damage and liver fibrosis is critical in preventing end-stage liver disease (ESLD). The complex biological events in liver fibrosis involve cellular, molecular, and immunological changes, transforming the normal hepatic microenvironment into a fibrotic liver. This process causes injury, inflammation, hepatic stellate cell activation, ECM deposition, and architectural remodelling.
 |
| Leaver fibrosis |
What Causes Hepatic Fibrosis?
Hepatic fibrosis is a pathological condition characterised by the excessive accumulation of extracellular matrix (ECM) proteins, including collagen, in response to chronic liver injury. It is a progressive process that, if untreated, can lead to cirrhosis, liver failure, or hepatocellular carcinoma (HCC). The primary driver of fibrosis is chronic liver injury, which triggers inflammation, an immune response, and rising hepatic stellate cells (HSCs), resulting in scar tissue formation.
Below are the major causes of hepatic fibrosis:
1. Chronic Viral Hepatitis (Hepatitis B, C, and D)
Mechanism:
- Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) trigger chronic inflammation in the liver.
- Persistent inflammation causes hepatocyte death and stimulates Kupffer cells (liver macrophages) to release pro-inflammatory cytokines like:
- TGF-β (Transforming Growth Factor-beta)
- PDGF (Platelet-Derived Growth Factor)
- These cytokines activate hepatic stellate cells (HSCs), transforming them into myofibroblasts that secrete collagen and ECM proteins, leading to fibrosis.
Why Does Fibrosis Persist in Viral Hepatitis?
- Chronic viral replication induces constant liver cell damage.
- This fibrosis triggers continuous HSC activation and collagen deposition, resulting in fibrosis.
- In Hepatitis C, fibrosis progresses rapidly to cirrhosis if untreated.
Risk Factors for Fibrosis in Viral Hepatitis:
- Duration of infection (more than 6 months = chronic hepatitis)
- Alcohol consumption
- Co-infection with HIV or Hepatitis D
- Metabolic disorders (diabetes, obesity, NAFLD)
2. Alcoholic Liver Disease (ALD) – Chronic Alcohol Abuse
Mechanism:
- Chronic and excessive alcohol consumption damages hepatocytes through:
- Oxidative stress → generates reactive oxygen species (ROS)
- Lipopolysaccharide (LPS) from gut microbiota → Promotes inflammation
- Damaged hepatocytes release pro-inflammatory cytokines, leading to:
- Activation of Kupffer cells → Secretion of TGF-β
- Activation of hepatic stellate cells (HSCs) → Collagen deposition
How Does Alcohol Cause Fibrosis?
- Chronic alcohol intake reduces anti-fibrotic enzymes, preventing ECM degradation.
- Increases oxidative stress and inflammation, accelerating fibrosis progression.
- Steatohepatitis (fatty liver with inflammation) leads to fibrosis in advanced stages.
Alcohol Consumption Threshold for Fibrosis:
- Men: >30-40 grams/day for 10+ years
- Women: >20-30 grams/day for 10+ years
 |
| Liver fibrosis scanning |
3. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)
Mechanism:
- Excessive fat accumulates in the liver (steatosis) without alcohol intake, causing NAFLD.
- In some individuals, simple steatosis progresses to NASH (Non-Alcoholic Steatohepatitis) due to:
- Lipotoxicity (fat-induced liver injury)
- Inflammation and oxidative stress
- NASH activates hepatic stellate cells (HSCs), promoting excessive collagen synthesis and fibrosis.
Risk Factors for Fibrosis in NAFLD/NASH:
- Obesity (BMI >30)
- Type 2 Diabetes
- Insulin resistance
- Dyslipidemia (high cholesterol and triglycerides)
- Sedentary lifestyle
Why Is Fibrosis Rapid in NASH?
- In NASH, continuous hepatocyte injury leads to persistent HSC activation.
- Increased insulin resistance and lipotoxicity promote ECM accumulation.
4. Chronic Cholestatic Liver Diseases
Bile flow obstruction triggers cholestatic liver diseases, leading to:
- Bile acid accumulation → Toxic to hepatocytes
- Chronic inflammation → Activates Kupffer cells and HSCs
- Excessive ECM deposition → Fibrosis development
Major Cholestatic Liver Diseases Leading to Fibrosis:
DiseaseCauseFibrosis Mechanism
Primary Biliary Cholangitis (PBC)-Autoimmune destruction of bile ducts Chronic inflammation → Fibrosis
Primary Sclerosing Cholangitis (PSC)-Bile duct scarring (autoimmune or idiopathic) Cholestasis → Fibrosis
Bile Duct Obstruction (CBD Stones) Gallstones blocking bile flow-Obstructive injury → Fibrosis
5. Autoimmune Hepatitis (AIH)
Mechanism:
- In autoimmune hepatitis, the immune system attacks hepatocytes, causing:
- Chronic inflammation
- Massive hepatocyte damage
- Persistent HSC activation
- Activated HSCs continuously deposit collagen, leading to progressive fibrosis.
Why Is Fibrosis Aggressive in AIH?
- The autoimmune response remains persistent despite treatment.
- Severe fibrosis can progress rapidly to cirrhosis or liver failure.
Triggers of AIH:
- Genetic predisposition
- Viral infections
- Environmental toxins
- Other autoimmune diseases (thyroiditis, rheumatoid arthritis, etc.)
6. Parasitic and Bacterial Infections
Parasitic Infections Leading to Fibrosis:
- Schistosomiasis:
- Parasitic worms (Schistosoma) infect the liver.
- Cause granuloma formation and severe liver fibrosis.
- Hydatid Disease (Echinococcosis):
- Liver cysts formed by Echinococcus granulosus.
- Prolonged inflammation triggers fibrosis.
Bacterial Infections:
- Liver abscesses caused by bacterial infections can induce fibrosis.
- Chronic bacterial hepatitis (e.g., tuberculosis, brucellosis) also triggers fibrosis.
7. Drug-Induced Liver Injury (DILI)
Drugs Causing Liver Fibrosis:
- Methotrexate (MTX): Used in rheumatoid arthritis, psoriasis, and cancers.
- Isoniazid (INH): Used in tuberculosis treatment.
- Amiodarone: Used in heart arrhythmia.
- Tamoxifen: Used in breast cancer therapy.
Mechanism:
- Long-term drug use induces hepatotoxicity, → Hepatocyte death, → Chronic inflammation, → Fibrosis.
8. Genetic and Metabolic Disorders
Hereditary Hemochromatosis (Iron Overload):
- Excessive iron accumulation leads to:
- Oxidative stress
- Hepatocyte death
- Fibrosis development
Wilson’s Disease (Copper Overload):
- Abnormal copper accumulation in the liver leads to chronic inflammation → Fibrosis.
Alpha-1 Antitrypsin Deficiency:
- Genetic defects lead to misfolded proteins accumulating in the liver.
- Persistent inflammation causes fibrosis.
9. Ischemic Liver Injury (Hypoxia-Induced Fibrosis)
- In cardiac failure, sepsis, or hypotension, liver perfusion decreases.
- Reduced blood supply causes hypoxic injury, triggering fibrosis.
- Known as Ischemic Hepatitis or Congestive Hepatopathy.
10. Idiopathic (Unknown Cause) Fibrosis
- In some cases, fibrosis develops without a clear cause.
- Possible triggers may include:
- Genetic mutations
- Undiagnosed viral infections
- Environmental toxins
- Gut dysbiosis (altered gut microbiome)
How do experts treat liver Fibrosis disease?
Treatment Strategies for Liver Fibrosis
Liver fibrosis occurs due to chronic liver injury, where excessive extracellular matrix (ECM) deposits replace healthy liver tissue. Effective treatment halts fibrosis progression, promotes liver regeneration, and reverses fibrotic damage.
1. Addressing the Underlying Cause
The first and most effective way to treat liver fibrosis is to eliminate the primary cause:
- Chronic Hepatitis B & C → Antiviral therapy (e.g., Entecavir, Tenofovir for HBV; Direct-acting antivirals (DAAs) for HCV)
- Non-Alcoholic Fatty Liver Disease (NAFLD)/NASH → Lifestyle changes, weight loss, metformin, GLP-1 receptor agonists (e.g., Semaglutide)
- Alcoholic Liver Disease (ALD) → Alcohol cessation, nutritional support
- Cholestatic Liver Diseases (PBC, PSC) → Ursodeoxycholic acid (UDCA), obeticholic acid (OCA)
- Metabolic Disorders (Hemochromatosis, Wilson’s disease, Alpha-1 Antitrypsin Deficiency) → Iron chelation, Copper chelation, A1AT replacement therapy
2. Targeting Hepatic Stellate Cells (HSCs) – The Fibrosis Drivers
- HSC Activation Inhibitors → Vitamin D analogues, PPAR-γ agonists (Pioglitazone)
- Apoptosis Inducers for Activated HSCs → Natural compounds (Curcumin, Resveratrol), Gliotoxin
- Anti-Inflammatory & Antifibrotic Drugs → Losartan (angiotensin receptor blocker), Cenicriviroc (CCR2/CCR5 antagonist)
3. Promoting ECM Degradation & Collagen Breakdown
- Matrix Metalloproteinase (MMP) Activators → Belapectin (Galectin-3 inhibitor)
- TGF-β Pathway Inhibitors → Pirfenidone, Fresolimumab (Anti-TGF-β monoclonal antibody)
- Lysyl Oxidase-like 2 (LOXL2) Inhibitors → Simtuzumab (reduces collagen crosslinking)
4. Antifibrotic & Regenerative Therapies
- FXR Agonists → Obeticholic acid (OCA) improves bile acid metabolism & reduces fibrosis
- ASK1 Inhibitors → Selonsertib blocks oxidative stress-induced fibrogenesis
- Stem Cell Therapy → Mesenchymal Stem Cells (MSCs) promote liver regeneration
- Hepatocyte Growth Factor (HGF) Therapy → Stimulates liver repair and fibrosis reversal
5. Lifestyle & Supportive Therapies
- Dietary Modifications → Mediterranean diet, low-sugar intake, omega-3 fatty acids
- Weight Loss → Reduces liver fat, improves insulin resistance
- Exercise → Enhances liver function, reduces inflammation
- Antioxidant Therapy → N-acetylcysteine (NAC), Vitamin E (for NASH patients)
6. Advanced & Emerging Therapies
- Gene Therapy → Targeting pro-fibrotic genes (e.g., siRNA, CRISPR)
- Liver Transplantation → For end-stage cirrhosis or decompensated liver disease
- Microbiome Therapy → Probiotics, Fecal Microbiota Transplantation (FMT) for gut-liver axis modulation
Liver fibrosis reverses when experts eliminate the cause and begin antifibrotic therapy. Advanced fibrosis or cirrhosis requires multimodal treatment, and ongoing research is exploring targeted molecular therapies to reverse fibrosis and regenerate liver tissue.
Recent study for Hepatic fibrosis: This study identified the enzyme CYP1B1 as a biomarker and predictor of HSC activation and liver fibrosis in both patients and mice. Blocking CYP1B1 led to the buildup of trehalose, a sugar that was found for the first time to have anti-fibrotic properties. Additionally, treating mice with trehalose, its analog lactotrehalose, or a CYP1B1 inhibitor prevented the development of liver fibrosis.
 |
| Updated study |
Conclusion
Hepatic fibrosis is a complex pathological process caused by chronic liver injury from various sources, such as viruses, alcohol, metabolic disorders, or autoimmune diseases. Once fibrosis becomes progressive, it can lead to cirrhosis, liver failure, and cancer. However, early intervention targeting HSCs, ECM degradation, and inflammatory pathways can reverse fibrosis and restore normal liver function.
Persistent inflammation, oxidative stress, and hepatic stellate cell (HSC) activation drive excessive ECM deposition, leading to fibrosis. Early diagnosis and targeted therapies are critical to prevent fibrosis progression and its terminal stages, including cirrhosis and hepatocellular carcinoma (HCC).